Literature DB >> 34524669

Ex Vivo Expansion of Th2-Polarizing Immunotherapeutic iNKT Cells from Human Peripheral Blood.

Natasha K Khatwani1,2,3, Kelly J Andrews1,4,5, Asha B Pillai6,7,8,9.   

Abstract

iNKT cells, classified as innate lymphocytes with invariant TCRs, have been highlighted as a putative, "off-the-shelf" cellular immunotherapeutic strategy for the treatment of malignant and nonmalignant diseases. However, their paucity in human blood limits their immunotherapeutic applications. Herein we describe a rigorously optimized 21-day ex vivo expansion method to achieve log-fold increases in immunotherapeutic human iNKT cells.
© 2021. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Adoptive cellular therapy; Bone marrow transplantation; Cancer immunotherapy; Cytotoxicity; Hematopoietic stem cell transplantation; Immunotherapy; Leukemia; NKT cells; Transplantation; iNKT cells

Mesh：

Substances：

Year:  2021        PMID： 34524669      PMCID： PMC8733937          DOI： 10.1007/978-1-0716-1775-5_13

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN： 1064-3745


  17 in total

1.  Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.

Authors:  Aristeidis Chaidos; Scott Patterson; Richard Szydlo; Mohammed Suhail Chaudhry; Francesco Dazzi; Edward Kanfer; Donald McDonald; David Marin; Dragana Milojkovic; Jiri Pavlu; John Davis; Amin Rahemtulla; Katy Rezvani; John Goldman; Irene Roberts; Jane Apperley; Anastasios Karadimitris
Journal:  Blood       Date:  2012-02-27       Impact factor: 22.113

2.  TCR V alpha 24 and V beta 11 coexpression defines a human NK1 T cell analog containing a unique Th0 subpopulation.

Authors:  C Prussin; B Foster
Journal:  J Immunol       Date:  1997-12-15       Impact factor: 5.422

3.  Invariant natural killer T cell-natural killer cell interactions dictate transplantation outcome after alpha-galactosylceramide administration.

Authors:  Rachel D Kuns; Edward S Morris; Kelli P A Macdonald; Kate A Markey; Helen M Morris; Neil C Raffelt; Tatjana Banovic; Alistair L J Don; Vanessa Rowe; Angela C Burman; Andrew D Clouston; Camile Farah; Gurdyal S Besra; Petr A Illarionov; Mark J Smyth; Steven A Porcelli; Geoffrey R Hill
Journal:  Blood       Date:  2009-04-15       Impact factor: 22.113

4.  Expansion and CD2/CD3/CD28 stimulation enhance Th2 cytokine secretion of human invariant NKT cells with retained anti-tumor cytotoxicity.

Authors:  Kelly Andrews; Anouk A J Hamers; Xiaodian Sun; Geoffrey Neale; Katherine Verbist; Paige Tedrick; Kim E Nichols; Shalini Pereira; Daniel E Geraghty; Asha B Pillai
Journal:  Cytotherapy       Date:  2020-03-29       Impact factor: 5.414

5.  IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production.

Authors:  Jonathan M Coquet; Konstantinos Kyparissoudis; Daniel G Pellicci; Gurdyal Besra; Stuart P Berzins; Mark J Smyth; Dale I Godfrey
Journal:  J Immunol       Date:  2007-03-01       Impact factor: 5.422

6.  CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor.

Authors:  Natalie A Borg; Kwok S Wun; Lars Kjer-Nielsen; Matthew C J Wilce; Daniel G Pellicci; Ruide Koh; Gurdyal S Besra; Mandvi Bharadwaj; Dale I Godfrey; James McCluskey; Jamie Rossjohn
Journal:  Nature       Date:  2007-06-20       Impact factor: 49.962

7.  Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers.

Authors:  J L Matsuda; O V Naidenko; L Gapin; T Nakayama; M Taniguchi; C R Wang; Y Koezuka; M Kronenberg
Journal:  J Exp Med       Date:  2000-09-04       Impact factor: 14.307

8.  Host NKT cells can prevent graft-versus-host disease and permit graft antitumor activity after bone marrow transplantation.

Authors:  Asha B Pillai; Tracy I George; Suparna Dutt; Pearline Teo; Samuel Strober
Journal:  J Immunol       Date:  2007-05-15       Impact factor: 5.422

9.  CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution.

Authors:  L Brossay; M Chioda; N Burdin; Y Koezuka; G Casorati; P Dellabona; M Kronenberg
Journal:  J Exp Med       Date:  1998-10-19       Impact factor: 14.307

10.  An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans.

Authors:  O Lantz; A Bendelac
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.